SB45-SSA2-SA4,96,424(2) The office of the public intervenor may levy an assessment on each insurer
1that is authorized to engage in the business of insurance in this state. The 2assessment levied under this subsection shall be based on the insurer’s premium 3volume for disability insurance policies, as defined in s. 632.895 (1) (a), written in 4this state. SB45-SSA2-SA4,96,65(3) The commissioner may provide by rule for the governance, duties, and 6administration of the office of the public intervenor. SB45-SSA2-SA4,96,108601.31 (1) (mv) For initial issuance or renewal of a license as a pharmacy 9benefit management broker or consultant under s. 628.495, amounts set by the 10commissioner by rule. SB45-SSA2-SA4,96,1312601.31 (1) (nv) For issuing or renewing a license as a pharmaceutical 13representative under s. 632.863, an amount to be set by the commissioner by rule. SB45-SSA2-SA4,96,1715601.31 (1) (nw) For issuing or renewing a license as a pharmacy services 16administrative organization under s. 632.864, an amount to be set by the 17commissioner by rule. SB45-SSA2-SA4,96,2419601.41 (14) Value-based diabetes medication pilot project. The 20commissioner shall develop a pilot project to direct a pharmacy benefit manager, as 21defined in s. 632.865 (1) (c), and a pharmaceutical manufacturer to create a value-22based, sole-source arrangement to reduce the costs of prescription medication used 23to treat diabetes. The commissioner may promulgate rules to implement this 24subsection. SB45-SSA2-SA4,97,102601.45 (1) Costs to be paid by examinees. The reasonable costs of 3examinations and audits under ss. 601.43, 601.44, 601.455, and 601.83 (5) (f) shall 4be paid by examinees except as provided in sub. (4), either on the basis of a system 5of billing for actual salaries and expenses of examiners and other apportionable 6expenses, including office overhead, or by a system of regular annual billings to 7cover the costs relating to a group of companies, or a combination of such systems, 8as the commissioner may by rule prescribe. Additional funding, if any, shall be 9governed by s. 601.32. The commissioner shall schedule annual hearings under s. 10601.41 (5) to review current problems in the area of examinations. SB45-SSA2-SA4,97,1312601.455 Fair claims processing, health insurance transparency, and 13claim denial rate audits. (1) Definitions. In this section: SB45-SSA2-SA4,97,1914(a) “Claim denial” means the refusal by an insurer to provide payment under 15a disability insurance policy for a service, treatment, or medication recommended 16by a health care provider. “Claim denial” includes the prospective refusal to pay for 17a service, treatment, or medication when a disability insurance policy requires 18advance approval before a prescribed medical service, treatment, or medication is 19provided. SB45-SSA2-SA4,97,2020(b) “Disability insurance policy” has the meaning given in s. 632.895 (1) (a). SB45-SSA2-SA4,97,2121(c) “Health care provider” has the meaning given in s. 146.81 (1) (a) to (p). SB45-SSA2-SA4,97,2422(2) Claims processing. (a) Insurers shall process each claim for a disability 23insurance policy within a time frame that is reasonable and prevents an undue 24delay in an insured’s care, taking into account the medical urgency of the claim. SB45-SSA2-SA4,98,4
1(b) If an insurer determines additional information is needed to process a 2claim for a disability insurance policy, the insurer shall request the information 3from the insured within 5 business days of making the determination and shall 4provide at least 15 days for the insured to respond. SB45-SSA2-SA4,98,55(c) All claim denials shall include all of the following: SB45-SSA2-SA4,98,761. A specific and detailed explanation of the reason for the denial that cites 7the exact medical or policy basis for the denial. SB45-SSA2-SA4,98,1082. A copy of or a publicly accessible link to any policy, coverage rules, clinical 9guidelines, or medical evidence relied upon in making the denial decision, with 10specific citation to the provision justifying the denial. SB45-SSA2-SA4,98,13113. Additional documentation, medical rationale, or criteria that must be met 12or provided for approval of the claim, including alternative options available under 13the policy. SB45-SSA2-SA4,98,1614(d) If an insurer uses artificial intelligence or algorithmic decision-making in 15processing a claim for a disability insurance policy, the insurer must notify the 16insured in writing of that fact. The notice shall include all of the following: SB45-SSA2-SA4,98,19171. A disclosure that artificial intelligence or algorithmic decision-making was 18used at any stage in reviewing the claim, even if a human later reviewed the 19outcome. SB45-SSA2-SA4,98,22202. A detailed explanation of how the artificial intelligence or algorithmic 21decision-making reached its decision, including any factors the artificial 22intelligence or algorithmic decision-making weighed. SB45-SSA2-SA4,98,24233. A contact point for requesting a human review of the claim if the claim was 24denied. SB45-SSA2-SA4,99,3
1(3) Independent review of denials. In addition to an insured’s right to an 2independent review under s. 632.835, as applicable, insureds have the right to 3request a review by the office of the public intervenor of any claim denial. SB45-SSA2-SA4,99,54(4) Prohibited practices. An insurer may not do any of the following with 5respect to a disability insurance policy: SB45-SSA2-SA4,99,66(a) Use vague or misleading policy terms to justify a claim denial. SB45-SSA2-SA4,99,77(b) Fail to provide a specific and comprehensible reason for a claim denial. SB45-SSA2-SA4,99,98(c) Cancel coverage under the policy after a claim is submitted due to alleged 9misstatements on the policy application. SB45-SSA2-SA4,99,1110(d) Deny a claim based on hidden or ambiguous exclusions in a disability 11insurance policy. SB45-SSA2-SA4,99,1212(e) Stall review of a claim to avoid timely payment. SB45-SSA2-SA4,99,1413(f) Reject a claim without reviewing all relevant medical records or consulting 14qualified experts. SB45-SSA2-SA4,99,1615(g) Fail to properly review or respond to an insured’s appeal in a timely 16manner. SB45-SSA2-SA4,99,1817(h) Allow non-physician personnel to determine whether care is medically 18necessary. SB45-SSA2-SA4,99,2019(i) Apply different medical necessity criteria based on financial interests 20rather than patient needs. SB45-SSA2-SA4,99,2221(j) Disregard a treating health care provider’s medical assessment without a 22valid clinical reason. SB45-SSA2-SA4,99,2423(k) Mandate prior approval for routine or urgent procedures in a manner that 24causes harmful delays. SB45-SSA2-SA4,100,3
1(L) For a disability insurance policy that provides coverage of emergency 2medical services, refuse to cover emergency medical services provided by out-of-3network providers. SB45-SSA2-SA4,100,54(m) List a health care provider as in-network on a provider directory and then 5deny a claim by stating the health care provider is out-of-network. SB45-SSA2-SA4,100,76(n) Deny coverage based on age, gender, disability, or a chronic condition 7rather than medical necessity. SB45-SSA2-SA4,100,98(o) Apply stricter standards in reviewing claims related to mental health 9conditions than claims related to physical health conditions. SB45-SSA2-SA4,100,1110(p) Perform a blanket denial of claims for high-cost conditions without an 11individualized review of each claim. SB45-SSA2-SA4,100,1212(r) Reclassify a claim to a lower-cost treatment to reduce insurer payout. SB45-SSA2-SA4,100,1413(s) Require an insured to fail a cheaper treatment before approving coverage 14for necessary care. SB45-SSA2-SA4,100,1515(t) Manipulate cost-sharing rules to shift higher costs to insureds. SB45-SSA2-SA4,100,2016(5) Transparency and reporting. (a) Beginning on January 1, 2027, an 17insurer shall annually publish a report detailing the insurer’s claim denial rates, 18reasons for claim denials, and the outcome of any appeal of a claim denial for the 19previous year for all disability insurance policies under which the insurer provides 20coverage. SB45-SSA2-SA4,100,2221(b) The commissioner shall maintain a public database of insurers’ claim 22denial rates and the outcomes of independent reviews under s. 632.835. SB45-SSA2-SA4,101,223(c) Beginning on January 1, 2027, an insurer that uses artificial intelligence 24or algorithmic decision-making in claims processing shall annually publish a report
1detailing all of the following for the previous year for all disability insurance policies 2under which the insurer provides coverage: SB45-SSA2-SA4,101,431. The percentage of claims submitted to the insurer that were reviewed by 4artificial intelligence or algorithmic decision-making. SB45-SSA2-SA4,101,752. The claim denial rate of claims reviewed by artificial intelligence or 6algorithmic decision-making compared to the claim denial rate of claims reviewed 7by humans. SB45-SSA2-SA4,101,983. The steps the insurer takes to ensure fairness and accuracy in decisions 9made by artificial intelligence or algorithmic decision-making. SB45-SSA2-SA4,101,1310(6) Claim denial rate audits. (a) The commissioner may conduct an audit 11of an insurer if the insurer’s claim denials are of such frequency as to indicate a 12general business practice. This paragraph is supplemental to and does not limit 13any other powers or duties of the commissioner. SB45-SSA2-SA4,101,1514(b) The commissioner may collect any relevant information from an insurer 15that is necessary to conduct an audit under par. (a). SB45-SSA2-SA4,101,1716(c) The commissioner may contract with a 3rd party to conduct an audit under 17par. (a). SB45-SSA2-SA4,101,2218(d) The commissioner may, based on the findings of an audit under par. (a), 19order the insurer who is the subject of the audit to comply with a corrective action 20plan approved by the commissioner. The commissioner shall specify in any 21corrective action plan under this paragraph the deadline by which an insurer must 22be in compliance with the corrective action plan. SB45-SSA2-SA4,101,2423(e) An insurer who is the subject of an audit under par. (a) shall provide a 24written response to any adverse findings of the audit. SB45-SSA2-SA4,102,3
1(f) If an insurer fails to comply with a corrective action plan under par. (d) by 2the deadline specified by the commissioner, the commissioner may order the 3insurer to pay a forfeiture pursuant to s. 601.64 (3). SB45-SSA2-SA4,102,74(7) Forfeitures. A violation of this section that results in a harmful delay in 5an insured’s care or an adverse health outcome for an insured shall be subject to a 6civil forfeiture of $10,000 per occurrence, in addition to any other penalties provided 7in s. 601.64 (3) or other law. SB45-SSA2-SA4,102,149601.575 Prescription drug importation program. (1) Importation 10program requirements. The commissioner, in consultation with persons 11interested in the sale and pricing of prescription drugs and appropriate officials 12and agencies of the federal government, shall design and implement a prescription 13drug importation program for the benefit of residents of this state, that generates 14savings for residents, and that satisfies all of the following: SB45-SSA2-SA4,102,1715(a) The commissioner shall designate a state agency to become a licensed 16wholesale distributor or to contract with a licensed wholesale distributor and shall 17seek federal certification and approval to import prescription drugs. SB45-SSA2-SA4,102,1918(b) The program shall comply with relevant requirements of 21 USC 384, 19including safety and cost savings requirements. SB45-SSA2-SA4,102,2120(c) The program shall import prescription drugs from Canadian suppliers 21regulated under any appropriate Canadian or provincial laws. SB45-SSA2-SA4,102,2322(d) The program shall have a process to sample the purity, chemical 23composition, and potency of imported prescription drugs. SB45-SSA2-SA4,103,324(e) The program shall import only those prescription drugs for which
1importation creates substantial savings for residents of this state and only those 2prescription drugs that are not brand-name drugs and that have fewer than 4 3competitor prescription drugs in the United States. SB45-SSA2-SA4,103,54(f) The commissioner shall ensure that prescription drugs imported under the 5program are not distributed, dispensed, or sold outside of this state. SB45-SSA2-SA4,103,66(g) The program shall ensure all of the following: SB45-SSA2-SA4,103,871. Participation by any pharmacy or health care provider in the program is 8voluntary. SB45-SSA2-SA4,103,1092. Any pharmacy or health care provider participating in the program has the 10appropriate license or other credential in this state. SB45-SSA2-SA4,103,13113. Any pharmacy or health care provider participating in the program charges 12a consumer or health plan the actual acquisition cost of the imported prescription 13drug that is dispensed. SB45-SSA2-SA4,103,1714(h) The program shall ensure that a payment by a health plan or health 15insurance policy for a prescription drug imported under the program reimburses no 16more than the actual acquisition cost of the imported prescription drug that is 17dispensed. SB45-SSA2-SA4,103,1918(i) The program shall ensure that any health plan or health insurance policy 19participating in the program does all of the following: SB45-SSA2-SA4,103,21201. Maintains a formulary and claims payment system with current 21information on prescription drugs imported under the program. SB45-SSA2-SA4,104,2222. Bases cost-sharing amounts for participants or insureds under the plan or
1policy on no more than the actual acquisition cost of the prescription drug imported 2under the program that is dispensed to the participant or insured. SB45-SSA2-SA4,104,533. Demonstrates to the commissioner or a state agency designated by the 4commissioner how premiums under the plan or policy are affected by savings on 5prescription drugs imported under the program. SB45-SSA2-SA4,104,86(j) Any wholesale distributor importing prescription drugs under the program 7shall limit its profit margin to the amount established by the commissioner or a 8state agency designated by the commissioner. SB45-SSA2-SA4,104,109(k) The program may not import any generic prescription drug that would 10violate federal patent laws on branded products in the United States. SB45-SSA2-SA4,104,1511(L) The program shall comply with tracking and tracing requirements of 21 12USC 360eee and 360eee-1, to the extent practical and feasible, before the 13prescription drug to be imported comes into the possession of this state’s wholesale 14distributor and fully after the prescription drug to be imported is in the possession 15of this state’s wholesale distributor. SB45-SSA2-SA4,104,1716(m) The program shall establish a fee or other mechanism to finance the 17program that does not jeopardize significant savings to residents of this state. SB45-SSA2-SA4,104,1818(n) The program shall have an audit function that ensures all of the following: SB45-SSA2-SA4,104,20191. The commissioner has a sound methodology to determine the most cost-20effective prescription drugs to include in the program. SB45-SSA2-SA4,104,22212. The commissioner has a process in place to select Canadian suppliers that 22are high quality, high performing, and in full compliance with Canadian laws. SB45-SSA2-SA4,105,2
13. Prescription drugs imported under the program are pure, unadulterated, 2potent, and safe. SB45-SSA2-SA4,105,334. The program is complying with the requirements of this subsection. SB45-SSA2-SA4,105,545. The program is adequately financed to support administrative functions of 5the program while generating significant cost savings to residents of this state. SB45-SSA2-SA4,105,766. The program does not put residents of this state at a higher risk than if the 7program did not exist.
/2025/related/amendments/sb45/sa4_ssa2_sb45
true
amends
/2025/related/amendments/sb45/sa4_ssa2_sb45/188/_17
amends/2025/REG/SB45-SSA2-SA4,99,6
amends/2025/REG/SB45-SSA2-SA4,99,6
section
true